Fucoidan Alleviates Renal Fibrosis in Diabetic Kidney Disease via Inhibition of NLRP3 Inflammasome-Mediated Podocyte Pyroptosis

Background: Fucoidan (FPS) has been widely used to treat renal fibrosis (RF) in patients with diabetic kidney disease (DKD); however, the precise therapeutic mechanisms remain unclear. Recently, research focusing on inflammation-derived podocyte pyroptosis in DKD has attracted increasing attention....

Повний опис

Бібліографічні деталі

Автори:	Mei-Zi Wang, Jie Wang, Dong-Wei Cao, Yue Tu, Bu-Hui Liu, Can-Can Yuan, Huan Li, Qi-Jun Fang, Jia-Xin Chen, Yan Fu, Bing-Ying Wan, Zi-Yue Wan, Yi-Gang Wan, Guo-Wen Wu
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Frontiers Media S.A. 2022-03-01
Серія:	Frontiers in Pharmacology
Предмети:	fucoidan diabetic kidney disease renal fibrosis podocyte pyroptosis NLRP3 inflammasome
Онлайн доступ:	https://www.frontiersin.org/articles/10.3389/fphar.2022.790937/full
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!